Compare TSQ & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | ANVS |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 111.3M |
| IPO Year | 2000 | 2020 |
| Metric | TSQ | ANVS |
|---|---|---|
| Price | $6.12 | $3.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.50 | ★ $13.50 |
| AVG Volume (30 Days) | 69.7K | ★ 506.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 13.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $5.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $1.11 |
| 52 Week High | $9.38 | $5.50 |
| Indicator | TSQ | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 67.40 | 41.84 |
| Support Level | $5.43 | $2.70 |
| Resistance Level | $5.79 | $3.30 |
| Average True Range (ATR) | 0.26 | 0.27 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 93.67 | 26.38 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.